BRCA2 and breast carcinoma: Using the Breast CFR, we found strong evidence that OC use was associated with a substantial (4.5‐fold; p = 0.0001) protective association against breast cancer diagnosed before age 40 for BRCA1 carriers, but not for BRCA2 carriers or noncarriers (Milne et al., 2005).